8/2/2023 12:58:13 PM - Patient investors way watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. There was a "breakaway gap" as it spiked to a new high on 7/27/23 after reporting Jun &#39;23 quarterly earnings +176% on +15% sales revenues versus the year ago period. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>8/1/2023 12:57:21 PM - Patient investors way watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. There was a "breakaway gap" as it spiked to a new high on 7/27/23 after reporting Jun &#39;23 quarterly earnings +176% on +15% sales revenues versus the year ago period. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>7/31/2023 12:51:55 PM - Patient investors way watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. There was a &quot;breakaway gap&quot; as it spiked to a new high on 7/27/23 after reporting Jun &#39;23 quarterly earnings +176% on +15% sales revenues versus the year ago period. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>7/28/2023 1:02:45 PM - Patient investors way watch for a new base or secondary buy point to possibly develop an dbe noted in the weeks ahead. There was a "breakaway gap" as it spiked to a new high on the prior session after reporting Jun &#39;23 quarterly earnings +176% on +15% sales revenues versus the year ago period. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>7/20/2023 12:49:45 PM - Due to report Jun &#39;23 quarterly results on 7/26/23. Managed a "positive reversal" from today&#39;s early loss, rebounding near its 50 DMA line ($19.05) which may act as resistance after damaging volume-driven losses. It has not yet formed a base of sufficient length. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>6/27/2023 12:37:58 PM - Today&#39;s 4th consecutive loss has it pulling back near its 50 DMA line ($18.97) which has acted as support during its ongoing ascent.  Patient investors may watch for a new base or secondary buy point to develop and be noted in the weeks ahead. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>4/28/2023 12:53:50 PM - Found support at its 50 DMA line ($17.04) and it is hitting a new 52-week high with today&#39;s 2nd consecutive volume-driven gain, getting extended from the prior high. Patient investors may watch for a new base or secondary buy point to develop and be noted in the weeks ahead. Reported strong Sep, Dec &#39;22, and Mar &#39;23 quarterly results versus the year-ago periods, helping it better match the fact-based investment system&#39;s fundamental guidelines.<br><hr>4/27/2023 1:23:41 PM - Found support at its 50 DMA line ($17.04) and it wedged up to hit new 52-week highs with recent gains lacking great conviction. Noted with caution in prior mid-day reports - <i>"Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain."</i><br><hr>4/13/2023 12:24:56 PM - Found support at its 50 DMA line ($16.40) and it wedged up to hit a new 52-week high with recent gains lacking great conviction. Noted with caution in prior mid-day reports - <i>"Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain."</i><br><hr>4/11/2023 12:40:50 PM - Found support at its 50 DMA line ($16.27) and it has wedged back up near a 52-week high with recent gains lacking great conviction. Noted with caution in prior mid-day reports - <i>"Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain."</i><br><hr>3/20/2023 12:30:48 PM - Abruptly slumped back to its 50 DMA line ($15.50) last week after barely trading above its 2021 high ($17.79) when noted with caution in the 3/07/23 mid-day report - <i>"Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain."</i><br><hr>3/15/2023 12:14:54 PM - Abruptly slumping after barely trading above its 2021 high ($17.79) when last noted in the 3/07/23 mid-day report, falling near its 50 DMA line ($15.37) with today&#39;s 5th consecutive volume-driven loss. Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain.<br><hr>3/7/2023 12:47:53 PM - Recent volume-driven gains helped it trade above its 2021 high ($17.79). Making steady progress in recent weeks since finding support near its 50 DMA line. Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain.<br><hr>3/6/2023 12:10:57 PM - Today&#39;s gain is adding to recent volume-driven gains and helped it trade above its 2021 high ($17.79). Making steady progress in recent weeks since finding support near its 50 DMA line. Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain.<br><hr>2/27/2023 12:49:54 PM - Recent volume-driven gains have it approaching its 2021 high ($17.79). Making steady progress in recent weeks since finding support near its 50 DMA line. Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain.<br><hr>2/22/2023 12:42:07 PM - Recent volume-driven gains have it approaching its 2021 high ($17.79). Making steady progress in recent weeks since finding support near its 50 DMA line. Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain.<br><hr>2/21/2023 12:50:33 PM - On track today for a 3rd consecutive volume-driven gain while approaching its 2021 high ($17.79). Making steady progress in recent weeks since finding support near its 50 DMA line. Reported stronger Sep and Dec &#39;22 quarterly results but fundamental concerns remain.<br><hr>2/1/2023 12:38:02 PM - On track today for a 6th consecutive volume-driven gain. Making steady progress since rebounding above prior highs after recently finding support near its 50 DMA line. Reported stronger Sep &#39;22 quarterly results but fundamental concerns remain.<br><hr>1/27/2023 12:31:31 PM - Making steady progress since rebounding above prior highs after recently finding support near its 50 DMA line. Reported stronger Sep &#39;22 quarterly results but fundamental concerns remain.<br><hr>1/26/2023 12:47:40 PM - Making steady progress since rebounding above prior highs after recently finding support near its 50 DMA line. Reported stronger Sep &#39;22 quarterly results but fundamental concerns remain.<br><hr>1/9/2023 1:40:44 PM - Choppy consolidation continues while again rebounding above prior highs since finding support near its 50 DMA line. Reported stronger Sep &#39;22 quarterly results but fundamental concerns remain.<br><hr>3/18/2022 12:46:25 PM - Choppy consolidation continues while again rebounding above its 50 and 200 DMA lines this week. Reported strong Sep and Dec &#39;21 quarterly results but fundamental concerns remain.<br><hr>3/8/2022 12:50:42 PM - Reported strong Sep and Dec &#39;21 quarterly results but fundamental concerns remain. Consolidating above its 50 and 200 DMA lines since last noted with caution in the 10/29/21 mid-day report.<br><hr>10/29/2021 1:00:42 PM - Perched at its 52-week high following a volume-driven gain on the prior session. Reported strong Sep &#39;21 quarterly results but fundamental concerns remain.<br><hr>